These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 34652440)

  • 1. Immunogenicity and safety of a heterologous prime-boost COVID-19 vaccine schedule: ChAdOx1 vaccine Covishield followed by BBV152 Covaxin.
    Kant R; Dwivedi G; Zaman K; Sahay RR; Sapkal G; Kaushal H; Nyayanit DA; Yadav PD; Deshpande G; Singh R; Chaowdhary S; Gupta N; Kumar S; Abraham P; Panda S; Bhargava B
    J Travel Med; 2021 Dec; 28(8):. PubMed ID: 34652440
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inactivated vaccine Covaxin/BBV152: A systematic review.
    Ahmed TI; Rishi S; Irshad S; Aggarwal J; Happa K; Mansoor S
    Front Immunol; 2022; 13():863162. PubMed ID: 36016940
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sub-optimal neutralisation of omicron (B.1.1.529) variant by antibodies induced by vaccine alone or SARS-CoV-2 Infection plus vaccine (hybrid immunity) post 6-months.
    Medigeshi GR; Batra G; Murugesan DR; Thiruvengadam R; Chattopadhyay S; Das B; Gosain M; Ayushi ; Singh J; Anbalagan A; Shaman H; Pargai K; Mehdi F; Das SJ; Kahlon N; Singh S; Kshetrapal P; Wadhwa N; Pandey AK; Bhatnagar S; Garg PK
    EBioMedicine; 2022 Apr; 78():103938. PubMed ID: 35305396
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of BBV152/Covaxin and AZD1222/Covishield vaccines against severe COVID-19 and B.1.617.2/Delta variant in India, 2021: a multi-centric hospital-based case-control study.
    Bhatnagar T; Chaudhuri S; Ponnaiah M; Yadav PD; Sabarinathan R; Sahay RR; Ahmed F; Aswathy S; Bhardwaj P; Bilimale A; Kumar MS; Logaraj M; Narlawar U; Palanivel C; Patel P; Rai SK; Saxena V; Singh A; Thangaraj JW; Agarwal A; Alvi Y; Amoghashree ; Ashok P; Babu D; Bahurupi Y; Bhalavi S; Behera P; Biswas PP; Charan J; Chauhan NK; Chetak KB; Dar L; Das A; Deepashree R; Dhar M; Dhodapkar R; Dipu TS; Dudeja M; Dudhmal M; Gadepalli R; Garg MK; Gayathri AV; Goel AD; Gowdappa HB; Guleria R; Gupta MK; Islam F; Jain M; Jain V; Jawahar MLS; Joshi R; Kant S; Kar SS; Kalita D; Khapre M; Khichar S; Kombade SP; Kohli S; Kumar A; Kumar A; Kumar D; Kulirankal KG; Leela KV; Majumdar T; Mishra B; Misra P; Misra S; Mohapatra PR; Murthy MN; Nyayanit DA; Patel M; Pathania M; Patil S; Patro BK; Jalandra R; Rathod P; Shah N; Shete A; Shukla D; Shwethashree M; Sinha S; Sumana MN; Surana A; Trikha A; Tejashree A; Venkateshan M; Vijaykrishnan G; Wadhava S; Wig N; Gupta N; Abraham P; Murhekar MV
    Int J Infect Dis; 2022 Sep; 122():693-702. PubMed ID: 35843496
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity of two COVID-19 vaccines used in India: An observational cohort study in health care workers from a tertiary care hospital.
    Arankalle V; Kulkarni-Munje A; Kulkarni R; Palkar S; Patil R; Oswal J; Lalwani S; Mishra AC
    Front Immunol; 2022; 13():928501. PubMed ID: 36211366
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical evaluation of safety and immunogenicity of a primary series intranasal COVID-19 vaccine candidate (BBV154) and humoral immunogenicity evaluation of a heterologous prime-boost strategy with COVAXIN (BBV152).
    Sunagar R; Prasad SD; Ella R; Vadrevu KM
    Front Immunol; 2022; 13():1063679. PubMed ID: 36569867
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity and safety of homologous and heterologous booster vaccination of ChAdOx1 nCoV-19 (COVISHIELD™) and BBV152 (COVAXIN®): a non-inferiority phase 4, participant and observer-blinded, randomised study.
    Rose W; Raju R; Babji S; George A; Madhavan R; Leander Xavier JV; David Chelladurai JS; Nikitha OS; Deborah AA; Vijayakumar S; Immanuel S; John J; Rupali P; Abhilash KPP; Mohan VR; Tallapaka KB; Samuel P; Kang G
    Lancet Reg Health Southeast Asia; 2023 Jan; 12():100141. PubMed ID: 36712811
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Variants of concern responsible for SARS-CoV-2 vaccine breakthrough infections from India.
    Singh UB; Rophina M; Chaudhry R; Senthivel V; Bala K; Bhoyar RC; Jolly B; Jamshed N; Imran M; Gupta R; Aggarwal P; Divakar MK; Sinha S; Arvinden VR; Bajaj A; Shamnath A; Jain A; ; Scaria V; Sivasubbu S; Guleria R
    J Med Virol; 2022 Apr; 94(4):1696-1700. PubMed ID: 34786733
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Covid-19 Vaccines Available in India.
    Mukim M; Sharma P; Patweker M; Patweker F; Kukkar R; Patel R
    Comb Chem High Throughput Screen; 2022; 25(14):2391-2397. PubMed ID: 35293291
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized controlled trial of heterologous ChAdOx1 nCoV-19 and recombinant subunit vaccine MVC-COV1901 against COVID-19.
    Chen CJ; Yang LY; Chang WY; Huang YC; Chiu CH; Shih SR; Huang CG; Huang KA
    Nat Commun; 2022 Sep; 13(1):5466. PubMed ID: 36115850
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-World Effectiveness of COVID-19 Vaccine and Identification of SARS-CoV-2 Variants among People Living with HIV on Highly Active Antiretroviral Therapy in Central Kerala of India-An Ambi-Directional Cohort Study.
    Thomas J; Rajmohan P; Jose P; Kannan R; Jose R; Uttumadathil Gopinathan U; Raphael L; Baiju NM; Krishna S; Attokaran T; Bency A T J; Venugopal A; Sheela S; Kallempadam A; Jose L; Innah SJ; Varghese PR; George A
    Viruses; 2023 Oct; 15(11):. PubMed ID: 38005865
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inactivated COVID-19 vaccine BBV152/COVAXIN effectively neutralizes recently emerged B.1.1.7 variant of SARS-CoV-2.
    Sapkal GN; Yadav PD; Ella R; Deshpande GR; Sahay RR; Gupta N; Vadrevu KM; Abraham P; Panda S; Bhargava B
    J Travel Med; 2021 Jun; 28(4):. PubMed ID: 33772577
    [No Abstract]   [Full Text] [Related]  

  • 13. Immunogenic and reactogenic efficacy of Covaxin and Covishield: a comparative review.
    Das S; Kar SS; Samanta S; Banerjee J; Giri B; Dash SK
    Immunol Res; 2022 Jun; 70(3):289-315. PubMed ID: 35192185
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prime-Boost Vaccination With Covaxin/BBV152 Induces Heightened Systemic Cytokine and Chemokine Responses.
    Kumar NP; Banurekha VV; C P GK; Nancy A; Padmapriyadarsini C; Mary AS; Devi KRU; Murhekar M; Babu S
    Front Immunol; 2021; 12():752397. PubMed ID: 34721425
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune responses against different variants of SARS-CoV-2 including Omicron following 6 months of administration of heterologous prime-boost COVID-19 vaccine.
    Sapkal G; Kant R; Dwivedi G; Sahay RR; Yadav PD; Deshpande GR; Singh R; Nyayanit DA; Patil DY; Shete-Aich AM; Zaman K; Chaudhari AK; Gupta N; Panda S; Abraham P; Bhargava B
    J Travel Med; 2022 May; 29(3):. PubMed ID: 35244698
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Breakthrough SARS-CoV-2 infections among BBV-152 (COVAXIN®) and AZD1222 (COVISHIELD
    Dash GC; Subhadra S; Turuk J; Parai D; Rath S; Sabat J; Rout UK; Kanungo S; Choudhary HR; Nanda RR; Pattnaik M; Pati S; Bhattacharya D
    J Med Virol; 2022 Mar; 94(3):1201-1205. PubMed ID: 34622961
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diabetic ketoacidosis (DKA) in type 1 diabetes mellitus (T1DM) temporally related to COVID-19 vaccination.
    Ganakumar V; Jethwani P; Roy A; Shukla R; Mittal M; Garg MK
    Diabetes Metab Syndr; 2022 Jan; 16(1):102371. PubMed ID: 34954484
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Herpes simplex virus retinitis following ChAdOx1 nCoV- 19 (Covishield) vaccination for SARS CoV 2: A case report.
    Singh J; More A; Shetty SB; Chaskar P; Sen A
    Ocul Immunol Inflamm; 2022 Jul; 30(5):1282-1285. PubMed ID: 35587646
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adopting an heterologous prime-boost strategy in COVID-19 vaccination: the need for locally generated evidence in Africa.
    Oboh MA; Omoleke S; Salami K
    Pan Afr Med J; 2022; 41():148. PubMed ID: 35519174
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neutralization of Beta and Delta variant with sera of COVID-19 recovered cases and vaccinees of inactivated COVID-19 vaccine BBV152/Covaxin.
    Yadav PD; Sapkal GN; Ella R; Sahay RR; Nyayanit DA; Patil DY; Deshpande G; Shete AM; Gupta N; Mohan VK; Abraham P; Panda S; Bhargava B
    J Travel Med; 2021 Oct; 28(7):. PubMed ID: 34230972
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.